Simplifying Global Compliance
Nanomedicine Presents Unique Challenges to IRBs
Executive Briefing Series
Nanomedicine is an exciting new field that offers great promise, but much about this cutting-edge technology is unknown, which argues for a precautionary approach by institutional review boards (IRB) and researchers to protect all parties involved in nanomedicine trials, a National Institutes of Health- (NIH) funded panel says.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing